<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204138</url>
  </required_header>
  <id_info>
    <org_study_id>SU-08312010-6811</org_study_id>
    <nct_id>NCT01204138</nct_id>
  </id_info>
  <brief_title>Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA</brief_title>
  <acronym>CATARA</acronym>
  <official_title>Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      A Phase II, single institution, double blind, randomized, placebo controlled, cross-over&#xD;
      study exploring the safety and efficacy apremilast in patients with active RA with&#xD;
      concomitant use of TNF inhibition. Following a screening period, patients with active disease&#xD;
      on stable TNF inhibition will be randomized to receive either apremilast or placebo for a&#xD;
      period of 12 weeks. At the end of 12 weeks patients will be assessed for efficacy using the&#xD;
      ACR responder index looking for a 20% improvement, then all patients initially randomized and&#xD;
      treated in a blinded fashion with apremilast will be crossed over to placebo while those&#xD;
      patients initially randomized and treated with placebo will be crossed over to apremilast.&#xD;
      Patients will be followed for an additional 12 weeks on treatment to assess both safety and&#xD;
      efficacy of this combination treatment. Following 24 weeks of active treatment or early&#xD;
      termination, patients will undergo a 28 day safety visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of apremilast when used in&#xD;
      combination with a background DMARD and TNF inhibition in patients with active RA using the&#xD;
      ACR responder index looking for a 20% improvement.&#xD;
&#xD;
      To evaluate the safety and tolerability of apremilast when used in combination with TNF&#xD;
      inhibition in patients with active RA.&#xD;
&#xD;
      To evaluate the clinical outcomes in RA using the individual domains of the ACR responder&#xD;
      index1 .&#xD;
&#xD;
      To evaluate the clinical outcomes of RA using the Disease Activity Score (DAS28)2 To&#xD;
      investigate the effects of apremilast on change in cytokine plasma concentration levels (from&#xD;
      baseline to Week 12) and the achievement of an ACR response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    decision of sponsor to withdraw before initiation; 0 patients enrolled&#xD;
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% improvement based on ACR responder criteria</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR 50/70 and DAS</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient randomized to one of two arms, either placebo, or Apremilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to either placebo or apremilast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Apremilast 30mg BID</description>
    <arm_group_label>Apremilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  18 years of age at the time of signing the informed consent form.&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Must have a diagnosis of RA of at least 6 months duration based on the ACR criteria&#xD;
&#xD;
          -  Must have evidence of active disease with DAS-28 &gt; 3.8&#xD;
&#xD;
          -  May be on one of the following DMARDs for at least 12 weeks and at a stable dose for&#xD;
             at least 6 weeks:&#xD;
&#xD;
               -  Methotrexate 7.5-25mg/week&#xD;
&#xD;
               -  Hydroxychloroquine (200-400mg/day)&#xD;
&#xD;
          -  Must be on one of the following SQ TNF inhibitors at a stable, label approved dose for&#xD;
             at least 12 weeks:&#xD;
&#xD;
               -  adalimumab (Humira®, Abbott Laboratories, North Chicago, IL)&#xD;
&#xD;
               -  certolizumab pegol (Cimzia®, UCB, Inc, Smyrna, GA)&#xD;
&#xD;
               -  golimumab (Simponi®, Johnson &amp; Johnson, New Brunswick, NJ)&#xD;
&#xD;
               -  etanercept (Enbrel®, Amgen, Thousand Oaks, CA and Wyeth Pharmaceuticals,&#xD;
                  Philadelphia, PA)&#xD;
&#xD;
          -  Concommitant use of non-steroidal anti-inflammatory drugs and/or oral corticosteroids&#xD;
             (prednisone&lt;10mg/day or equivalent) are permitted if doses have been stable for at&#xD;
             least 14 days.&#xD;
&#xD;
          -  If taking methotrexate, patient must also be taking folic or folinic acid at at dose&#xD;
             of no less then 5mg/week.&#xD;
&#xD;
          -  Must meet the following laboratory criteria:&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               -  White blood cell (WBC) count; 3000 /;L (3.0 X 109/L) and 14,000/L (&lt; 14 X 109/L)&#xD;
&#xD;
               -  Platelets; 100,000 /L (100 X 109/L)&#xD;
&#xD;
               -  Serum creatinine; 1.5 mg/dL (or 133mol/L)&#xD;
&#xD;
               -  Total bilirubin; 2.0 mg/dL&#xD;
&#xD;
               -  Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and&#xD;
                  alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]); 1.5x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)‡ must have a negative urine pregnancy test at&#xD;
             screening (Visit 1). In addition, sexually active FCBP must agree to use TWO of the&#xD;
             following adequate forms of contraception while on study medication: oral, injectable,&#xD;
             or implantable hormonal contraceptives; tubal ligation; intrauterine device; barrier&#xD;
             contraceptive with spermicide; or vasectomized partner while on study. A FCBP must&#xD;
             agree to have pregnancy tests every 4 weeks while on study medication and for one&#xD;
             month after taking the last dose of study medication.&#xD;
&#xD;
          -  Males (including those who have had a vasectomy) must agree to use barrier&#xD;
             contraception (latex condoms) when engaging in reproductive sexual activity with FCBP&#xD;
             while on study medication and for 28 days after taking the last dose of study&#xD;
             medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide voluntary consent&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Systemic fungal infection&#xD;
&#xD;
          -  Active tuberculosis or a history of incompletely treated tuberculosis&#xD;
&#xD;
          -  History of recurrent bacterial infection (at least 3 major infections resulting in&#xD;
             hospitalization and/or requiring intravenous antibiotic treatment within the past 2&#xD;
             years)&#xD;
&#xD;
          -  Clinically significant abnormality on the chest x-ray (CXR) with anteriorposterior and&#xD;
             lateral views at screening. Chest x-rays performed within 3 months prior to start of&#xD;
             study drug are acceptable.&#xD;
&#xD;
          -  Use of any investigational medication within 4 weeks prior to start of study drug or 5&#xD;
             pharmacokinetic/pharmacodynamic half-lives (whichever is longer)&#xD;
&#xD;
          -  Any clinically significant abnormality on 12-lead ECG at screening&#xD;
&#xD;
          -  History of congenital or acquired immunodeficiency (eg, Common Variable&#xD;
             Immunodeficiency [CVID])&#xD;
&#xD;
          -  Hepatitis B surface antigen positive or Hepatitis B core antibody positive at&#xD;
             screening&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Antibodies to Hepatitis C at screening&#xD;
&#xD;
          -  History of malignancy within 5 years prior to the screening visit (except for treated&#xD;
             [i.e. cured] basal cell skin carcinomas and treated [i.e. cured] carcinoma in situ of&#xD;
             the cervix)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Genovese</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mark Genovese</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>RA, treatment, TNF, cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

